USPTO granted patent US12590162B2 on March 31, 2026, covering a method of treating cancer by administering an effective amount of trichostatin A (TSA). The patent was assigned to Vanda Pharmaceuticals Inc. and names three inventors. The filing date was April 25, 2023, and the European application number is 18306601.

Patent holders and licensees should review the scope of the 5 granted claims to understand the extent of intellectual property protection. Competitors developing TSA-based cancer treatments should assess freedom-to-operate implications. Legal counsel may advise on international patent protection status and potential licensing opportunities.